Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05080166 | RECRUITING | Lymphoma

UPLYFT For Lymphoma Survivors
Sponsor:

Dana-Farber Cancer Institute

Information provided by (Responsible Party):

Oduni Odujide, MD

Brief Summary:

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Condition or disease

Lymphoma

Survivorship

Intervention/treatment

Interview with Clinicians

Field Test of UPLYFT with Lymphoma Survivors

Pilot of UPLYFT with Lymphoma Survivors

Phase

NA

Detailed Description:

This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors. Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program field test. Phase 2 is a randomized pilot study using the UPLFYT program finalized in Phase 1. Research procedures include: * In depth interview (lymphoma and mental health clinicians) * Screening for eligibility * 6 weekly intervention sessions (lymphoma survivors) * Baseline Assessments and Questionnaires (lymphoma survivors) 74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase 2. The American Society of Hematology is providing funding for the trial.

Study Type : INTERVENTIONAL
Estimated Enrollment : 74 participants
Masking : NONE
Primary Purpose : SUPPORTIVE_CARE
Official Title : An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors
Actual Study Start Date : 2022-02-08
Estimated Primary Completion Date : 2025-12-31
Estimated Study Completion Date : 2026-03-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • Lymphoma Survivors Phase 1 and 2
    • * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
    • * Age ≥ 18 years
    • * Interval of 3 months to 24 months from completion of first-line treatment
    • * In complete remission after first line of treatment
    • * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
    • * Access to computer (for videoconferencing)
    • Lymphoma clinicians and mental health clinicians Phase 1
      • * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
      • * Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians
      Exclusion Criteria
      • Lymphoma Survivors Phase 1
        • * Age \< 18 years
        • * Concurrent other malignancy
        • * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
        • Lymphoma Survivors Phase 2
          • * Age \< 18 years
          • * Concurrent other malignancy
          • * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
          • * Our study will exclude members of the following special populations
            • * Adults unable to consent
            • * Individuals who are not yet adults (infants, children, teenagers)
            • * Pregnant women
            • * Prisoners
UPLYFT For Lymphoma Survivors

Location Details

NCT05080166

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215